Efficacy and safety of 12  weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

In conclusion, these data support the inclusion of participants with genotype 4 or 6 infection in the EBR/GZR phase 3 studies. EBR/GZR ± RBV was unsatisfactory for participants with genotype 2 or 5 infection.

Source: Journal of Viral Hepatitis - March 14, 2018 Category: Infectious Diseases Authors: A. Brown, C. H ézode, E. Zuckerman, G. R. Foster, A. Zekry, S. K. Roberts, F. Lahser, C. Durkan, C. Badshah, B. Zhang, M. Robertson, J. Wahl, E. Barr, B. Haber, Tags: ORIGINAL ARTICLE Source Type: research